Carol Pena
Overview
Explore the profile of Carol Pena including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
22
Citations
1767
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hadd A, Silvestro A, McKelvey B, Baden J, Bormann Chung C, Brown B, et al.
Clin Transl Sci
. 2025 Mar;
18(3):e70185.
PMID: 40070025
The use of a liquid biopsy to assess molecular residual disease (MRD) of solid tumors holds significant promise for improving outcomes for patients with cancer. Liquid biopsies are a minimally...
2.
Powles T, Chang Y, Yamamoto Y, Munoz J, Reyes-Cosmelli F, Peer A, et al.
Nat Med
. 2024 Jun;
30(9):2508-2516.
PMID: 38823511
Circulating tumor DNA (ctDNA) is emerging as a potential biomarker in early-stage urothelial cancer, but its utility in metastatic disease remains unknown. In the phase 3 KEYNOTE-361 study, pembrolizumab with...
3.
Lenz G, Hawkes E, Verhoef G, Haioun C, Lim S, Heo D, et al.
Leukemia
. 2024 Jan;
38(2):469-472.
PMID: 38200221
No abstract available.
4.
Merino Vega D, Nishimura K, Zariffa N, Thompson J, Hoering A, Cilento V, et al.
JCO Precis Oncol
. 2022 Aug;
6:e2100372.
PMID: 35952319
Purpose: As immune checkpoint inhibitors (ICI) become increasingly used in frontline settings, identifying early indicators of response is needed. Recent studies suggest a role for circulating tumor DNA (ctDNA) in...
5.
Wick A, Bahr O, Schuler M, Rohrberg K, Chawla S, Janku F, et al.
Clin Cancer Res
. 2021 Feb;
27(10):2723-2733.
PMID: 33622704
Purpose: BAY1436032, an inhibitor of mutant isocitrate dehydrogenase 1 (mIDH1), was active against multiple IDH1-R132X solid tumors in preclinical models. This first-in-human study was designed to determine the safety and...
6.
Ramanathan R, Von Hoff D, Eskens F, Blumenschein Jr G, Richards D, Genvresse I, et al.
Target Oncol
. 2020 Oct;
15(6):803.
PMID: 33108585
The article Phase Ib Trial of the PI3K Inhibitor Copanlisib Combined with the Allosteric MEK Inhibitor Refametinib in Patients with Advanced Cancer.
7.
Ramanathan R, Von Hoff D, Eskens F, Blumenschein Jr G, Richards D, Genvresse I, et al.
Target Oncol
. 2020 Apr;
15(2):163-174.
PMID: 32314268
Background: Dual inhibition of PI3K and MAPK signaling is conceptually a promising anticancer therapy. Objective: This phase 1b trial investigated the safety, maximum tolerated dose (MTD), recommended phase II dose,...
8.
Lenz G, Hawkes E, Verhoef G, Haioun C, Lim S, Heo D, et al.
Leukemia
. 2020 Feb;
34(8):2184-2197.
PMID: 32060403
Patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) have adverse outcomes. We evaluated the efficacy and safety of the phosphatidylinositol 3-kinase inhibitor copanlisib in patients with relapsed/refractory DLBCL and assessed...
9.
Pinyol R, Montal R, Bassaganyas L, Sia D, Takayama T, Chau G, et al.
Gut
. 2018 Aug;
68(6):1065-1075.
PMID: 30108162
Objective: Sorafenib is the standard systemic therapy for advanced hepatocellular carcinoma (HCC). Survival benefits of resection/local ablation for early HCC are compromised by 70% 5-year recurrence rates. The phase 3...
10.
Marme F, Gomez-Roca C, Graudenz K, Huang F, Lettieri J, Pena C, et al.
Cancer Chemother Pharmacol
. 2018 Feb;
81(4):727-737.
PMID: 29468456
Combining sorafenib and eribulin mesylate may provide synergistic antitumor activities with limited overlapping toxicities. This phase 1b, open-label, dose-escalation study evaluated safety, pharmacokinetics, maximum tolerated dose/recommended phase 2 dose (MTD/RP2D),...